Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment Angiogenesis plays fundamentally critical roles in solid-tumor pathogenesis, growth, invasion and metastasis. Endostatin, one of the most potent anti-angiogenic factors, was first isolated in Folkman’s lab in 1997, and was reported to dramatically shrink tumor blood formation. But its insoluble and unstable nature coupled with the high cost of synthesizing the endostatin protein doomed it for clinical cancer treatment. Intrigued by Folkman’s pioneering discoveries, Chinese scientists found a way to refold the protein, making it cost-effective to manufacture a recombinant human endostatin, a soluble and stable form of endostatin. A number of clinical studies have demonstrated the significant survival benefit of rh-endostatin in treating late stage non-small-cell lung carcinoma (NSCLC) and, as a result, rh-endostatin (Endostar®) was approved by the State Food and Drug Administration of China (CFDA) in September of 2005 as a treatment option for NSCLC. Since then, increasing bodies of clinical data and experience have been obtained from a variety of other different cancers, such as small cell lung cancer, NSCLC in other settings, including malignant serous effusion, melanoma, colon cancer, gastric cancer, breast cancer, nasopharyngeal cancers, and others. This review aims at summarizing current clinical data of rh-endostatin including its survival benefits, optimized dosages, routes of administration, recommended duration and frequency of treatment, predictive biomarkers, and its safety profile in lung cancers as well as other cancers. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment

Li, Kai; Shi, Mingliang; Qin, Shukui
Oncology and Therapy , Volume 6 (1) – Jan 2, 2018
Download PDF
23 pages

Loading next page...
 
/lp/springer-journals/current-status-and-study-progress-of-recombinant-human-endostatin-in-Dm0oroCWGc
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Healthcare Ltd., part of Springer Nature
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-017-0055-1
Publisher site
See Article on Publisher Site

Abstract

Angiogenesis plays fundamentally critical roles in solid-tumor pathogenesis, growth, invasion and metastasis. Endostatin, one of the most potent anti-angiogenic factors, was first isolated in Folkman’s lab in 1997, and was reported to dramatically shrink tumor blood formation. But its insoluble and unstable nature coupled with the high cost of synthesizing the endostatin protein doomed it for clinical cancer treatment. Intrigued by Folkman’s pioneering discoveries, Chinese scientists found a way to refold the protein, making it cost-effective to manufacture a recombinant human endostatin, a soluble and stable form of endostatin. A number of clinical studies have demonstrated the significant survival benefit of rh-endostatin in treating late stage non-small-cell lung carcinoma (NSCLC) and, as a result, rh-endostatin (Endostar®) was approved by the State Food and Drug Administration of China (CFDA) in September of 2005 as a treatment option for NSCLC. Since then, increasing bodies of clinical data and experience have been obtained from a variety of other different cancers, such as small cell lung cancer, NSCLC in other settings, including malignant serous effusion, melanoma, colon cancer, gastric cancer, breast cancer, nasopharyngeal cancers, and others. This review aims at summarizing current clinical data of rh-endostatin including its survival benefits, optimized dosages, routes of administration, recommended duration and frequency of treatment, predictive biomarkers, and its safety profile in lung cancers as well as other cancers.

Journal

Oncology and Therapy – Springer Journals

Published: Jan 2, 2018

References

  • Tumor angiogenesis
    Kerbel, RS
  • Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
    O’Reilly, MS; Boehm, T; Shing, Y; Fukar, N; Vasios, G; Lane, WS
  • Unraveling the mysteries of endostatin
    Fu, Y; Tang, H; Huang, Y
  • Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents
    Limaverde-Sousa, G; Sternberg, C; Ferreira, CG
  • Endostatin’s emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications[J]
    Walia, A; Yang, JF; Huang, YH
  • Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
    Boehm, T; Folkman, J; Browder, T
  • Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells
    Fukumoto, S; Morifuji, M; Katakura, Y; Nakamura, S
  • Evaluation of local curative effect of image—guided thermal ablation in the treatment of lung
    Liu, BD; Zhi, XY
  • Long term results of a randomized, double-blind, and placebo controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer
    Sun, Y; Wang, JW; Liu, YY; Yu, QT; Zhang, YP; Li, K
  • A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer
    Han, B; Xiu, Q; Wang, H; Shen, J; Gu, AQ; Luo, Y
  • The efficacy and safety of docetaxel combined with recombinant human endostatin in the treatment of non-small cell lung cancer with or without intolerance after treatment
    Wang, J; Li, K; Sun, T; Zhang, MJ; Li, WL; Yao, Q
  • Study on lung cancer cells expressing VEGFR2 and the impact on the effect of RHES combined with radiotherapy in the treatment of brain metastases
    Jiang, XD; Ding, MH; Qiao, Y; Liu, Y; Liu, L
  • Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of non-small cell lung cancer
    Zhang, R; Wang, ZY; Li, YH; Lu, YH; Wang, S; Yu, WX
  • Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer
    Jiang, XD; Dai, P; Wu, J; Song, DA; Yu, JM
  • Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer
    Bao, Y; Peng, F; Zhou, QC; Yu, ZH; Li, JC; Cheng, ZB
  • Treatment of non-resectable stage III NSCLC with continuous intravenous injection of Endostar: results from a phase II prospective multicenter clinical trial results
    Ma, HL; Hui, ZG; Zhao, LJ; Xu, YJ; Zhai, YR; Wu, RY
  • Effect of recombinant human endostatin combined with TP regimen on postoperative adjuvant therapy for non-small cell lung cancer
    Yang, YZ; Pan, LK; Qi, DL; Xin, L; Cui, Y; An, GY
  • Comparison of postoperative adjuvant chemotherapy with combined adjuvant chemotherapy and non-small cell lung cancer
    Zhao, J; Wang, W; Shang, LQ; Xiao, W; Li, XC; Song, WA
  • Effect of recombinant human endostatin combined with platinum-based postoperative adjuvant chemotherapy on non-small cell lung cancer
    Pan, F; Gu, AQ; Wang, WM; Jiang, LY
  • Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer
    Zhou, ZT; Zhou, FX; Wei, Q; Zou, LY; Qin, BF; Peng, XS
  • A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer
    Lu, S; Li, L; Luo, Y; Zhang, L; Wu, G; Chen, ZW
  • Clinical observation of recombinant human endostatin combined with carboplatin and etoposide in the treatment of advanced small cell lung cancer
    Chen, JH; Luo, YZ; Zhou, WW; Zhou, H; Wang, W
  • Intraventricular application of recombinant human endostatin and/or cisplatin in the treatment of malignant pleural effusion of the prospective, randomized, national multi-center clinical study
    Qin, SK; Yang, LQ; Liang, J; Cheng, Y; Tan, QH; Bi, JW
  • Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study [J]
    Zhou, JF; Bai, CM; Wang, YZ
  • Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients
    Xu, HX; Huang, XE; Qian, ZY; Xu, X; Li, Y; Li, CG
  • Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: a clinical study
    Li, BL; Hu, XL; Zhao, XH; Sun, HG; Zhou, CY; Zhang, Y
  • Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial
    Chen, Z; Guo, W; Cao, J; Lv, F; Zhang, W; Qiu, L
  • A meta-analysis of the short-term efficacy of degrading combined with chemotherapy in the treatment of advanced colorectal
    Pan, YQ; Jiao, GL
  • Clinical observation of recombinant human vascular endostatin combined with chemotherapy in the treatment of advanced metastatic colorectal cancer
    Qi, XY; Yu, ZY; Ouyang, XN; Wang, WW
  • Clinical observation of recombinant human endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer
    Guo, YB; Zhen, L; Zhu, WR; Xu, X; Li, Y; Li, CG
  • A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma
    Cui, C; Mao, L; Chi, Z; Si, L; Sheng, XN; Kong, Y
  • Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer
    Xu, R; Ma, N; Wang, F; Ma, L; Chen, R; Chen, R
  • Recombinant human endostatin combined with DCF regimen for neoadjuvant chemotherapy patients with advanced gastric cancer to improve the rate of radical surgery
    Qu, XL; Chai, NX; Wang, YJ; Han, Y; Zhang, Y; Tao, L
  • Meta analysis of recombinant human endostatin combined with chemotherapy in the treatment of advanced gastric cancer
    Su, H; Hu, B; Ji, CS; He, YF; Han, XH; Lv, YJ
  • A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286)
    Jin, T; Li, B; Chen, XZ
  • The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma
    Guan, Y; Li, A; Xiao, W; Liu, S; Chen, B; Lu, T
  • Clinical application of recombinant human endostatin combined with transcatheter arterial chemoembolization in the treatment of advanced liver cancer
    Du, HJ
  • Efficacy and safety of recombinant human endostatin in the treatment of advanced liver cancer by transcatheter arterial chemoembolization
    Su, Y; Zhou, ZH; Wang, Q
  • Meta-analysis of recombinant human endostatin injection combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma
    Lin, Q; Zhang, SY; Huang, N; Su, YH
  • Dynamic contrastenhanced MR imaging in a phase II study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer [J]
    Jia, Q; Xu, J; Jiang, W
  • Clinical study of endostatin combined with GP regimen in the treatment of metastatic triple-negative breast cancer
    Lu, Y; Huang, HX; Li, GS
  • The efficacy and safety of endostar combined with taxane-based regimens for HER-2-negative metastatic breast cancer patients
    Huang, W; Liu, J; Wu, F; Chen, K; Li, N; Hong, Y
  • Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus
    Zhong, Z; Gu, X; Zhang, Z; Wang, D; Qing, Y; Li, M
  • Clinical observation of XELOX regimen combined with Endostar in the treatment of advanced biliary cancers
    Ren, TJ; Shan, FX; Hou, JF; Xue, Q
  • Preliminary observation of GEMOX regimen combined with recombinant human endostatin in the treatment of advanced biliary cancers
    Li, R; Sk, Qin; Liu, XF; Gong, XL; Hua, HQ; Wang, L
  • Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer
    Su, A; Zhang, J; Pan, ZH; Zhou, QM; Lv, X
  • Clinical observation on treatment of advanced ovarian cancer with different routes of administration
    Zhang, C; Deng, WY; Li, N; Xu, YF; Zhang, YP; Wei, C
  • Short-term efficacy of recombinant human endostatin (Endu) combined with radiotherapy in the treatment of 48 cases of advanced cervical cancer
    Ke, QH; ZhouSQ, HuY; Liu, Z; Zhang, WT; Su, XY
  • Simultaneous radiotherapy and chemotherapy combined with recombinant human endostatin in the treatment of 52 cases of advanced cervical cancer
    Ke, QH; Zhou, SH; Du, F; Huang, M; Luo, F; Lei, Y
  • Short-term efficacy of Endostar combined with gemcitabine in the treatment of advanced cervical cancer
    Nong, XS; Huang, XS; Mo, YF; Liang, D
  • Effects of endostar combined multidrug chemotherapy in osteosarcoma
    Xu, M; Xu, CX; Bi, WZ; Song, ZG; Jia, JP; Chai, W
  • A prospective, concurrent controlled non - randomized clinical study of chemotherapy combined with recombinant human endostatin in the treatment of stage IIB osteosarcoma
    Xu, HR; Li, B; Huang, Z; Zhang, Q; Niu, XH
  • A prospective, non-randomized clinical study of recombinant human endostatin combined with chemotherapy in the treatment of osteosarcoma
    Yan, HL; Zhang, ZC; Yang, QC; Qin, S; Dong, Y
  • Efficacy and safety of endostar combined with chemotherapy in patients with advanced soft tissue sarcomas
    Zhang, LP; Liao, XY; Xu, YM; Yan, LJ; Yan, GF; Wang, XX
  • Treatment of metastatic soft tissue sarcoma with recombinant human endostatin combined with chemotherapy Bed observation
    Huang, XF; Qu, Z; Hu, W; Zhang, N; Wang, YF; Wang, Y
  • Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
    Xing, P; Zhang, J; Yan, Z; Zhao, G; Li, X; Wang, G
  • Clinical study of recombinant human vascular endothelin combined with temozolomide in the treatment of recurrent high-grade gliomas
    Li, Y; Zhang, JP; Wang, ZW; Zhang, XZ; Zhou, WK
  • Recombinant human endostatin combined with cytotoxic drugs to rescue chemotherapy for recurrence of glioblastoma
    Zhang, JP; Teng, Y; Li, C
  • Recombinant human endostatin injection combined with chemotherapy for multi-cycle treatment of advanced non-small cell lung cancer
    Li, N; Jin, ZL; Liu, ZJ; Wang, J; Li, K
  • Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced non small cell lung cancer
    Hu, W; Fang, J; Nie, J; Dai, L; Zhang, J; Chen, XL
  • Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer
    Hansma, AH; Broxterman, HJ; Horst, I; Yuana, Y; Boven, E; Giaccone, G
  • Phase I study of continuous intravenous infusion of rh-endostatin combined with pemetrexed and carboplatin in advanced NSCLC
    Huang, Y; Yang, Y; Zhao, H; Ma, YX; Zou, QF; Zhang, L
  • Gene therapy with the angiogenesis inhibitor endostatin in an orthotopic lung cancer murine model
    Ning, T; Yan, X; Lu, ZJ; Wang, GP; Zhang, NG; Yang, JL
  • Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma
    Huang, G; Chen, L
  • Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model
    Li, N; Zheng, D; Wei, X; Jin, Z; Zhang, C; Li, K
  • Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models
    Peng, F; Xu, Z; Wang, J; Chen, YY; Li, Q; Zuo, YF
  • Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer
    Jiang, XD; Dai, P; Qiao, Y; Wu, J; Song, DA; Li, SQ
  • Application of CT perfusion imaging in evaluation of therapeutic effect of osteosarcoma
    Wu, CM; Ji, JY; Shi, X; Wu, M; Deng, G
  • Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor
    Huang, C; Wang, X; Wang, J; Lin, L; Liu, ZJ; Xu, WJ
  • Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer
    Crabb, SJ; Patsios, D; Sauerbrei, E; Ellis, PM; Arnold, A; Goss, G
  • Evaluation of the efficacy of anti-angiogenesis: how far is the new standard?
    Zhang, CC; Wang, J; Li, K
  • Circulating endothelium as an indication of vascular injury
    Bouvier, CA; Gaynor, E; Cintron, JR; Bernhardt, B; Spaet, TH
  • Circulating endothelial cells as biomarkers in clinicaloncology
    Mancuso, P; Bertolini, F
  • Circulating endothelial cells and tumor blood volume as predictors in lung cancer
    Wang, J; Xiao, J; Wei, X; Wang, L; Lin, L; Liu, Z
  • Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study
    Chu, TQ; Ding, H; Garfield, DH; Gu, AQ; Pei, J; Du, WD
  • Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy
    Yang, F; Tang, X; Riquelme, E; Behrens, C; Nilsson, MB; Giri, U
  • First clinical trials of endostatin yield lukewarm results
    Twombly, R
  • Clinical study of recombinant human endostatin (YH-16) injection in the treatment of advanced non-small cell lung cancer
    Shi, HL; Xu, LY; Liu, Z
  • Phase I Clinical study of recombinant human endostatin
    Yang, L; Wang, JW; Tang, ZM; Liu, XW; Huang, J; Li, ST
  • Recombinant human endostatin combined with NP regimen for the treatment of advanced NSCLC in a randomized, double-blind, controlled, multicenter phase III clinical study
    Wang, WJ; Sun, Y; Liu, Y; Yu, QT; Zhang, YP; Li, K
  • Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer[J]
    Yang, L; Wang, JW; Sun, Y; Zhu, YZ; Liu, XQ; Li, WL